Stephane Bancel - 13 Apr 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: MRNA
Reported as of: 13 Apr 2022
Net transaction value: -$3,218,247
SEC form: 4
Accepted by SEC: 15 Apr 2022, 15:16:43 UTC
Prior SEC filing: 08 Apr 2022
Next SEC filing: 22 Apr 2022
Source filing: View source filing
Reporting owner signature: /s/ Brian Sandstrom, as Attorney-in-Fact

Key filing fact

Stephane Bancel filed Form 4 for Moderna, Inc. (MRNA) on 15 Apr 2022.

Key facts

This page summarizes Stephane Bancel's Form 4 filing for Moderna, Inc. (MRNA).
9 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 15 Apr 2022, 15:16.

Change

Previous filing in this sequence was filed on 08 Apr 2022.
Current net transaction value: -$3,218,247.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRNA transaction

Common Stock

Sale

Transaction value: $21,228
Shares: -128
Change %: -0%
Price: $165.84
Shares after: 5,456,407
Date: 13 Apr 2022
Ownership: Direct
Footnotes: F1, F2

MRNA transaction

Common Stock

Sale

Transaction value: $116,795
Shares: -700
Change %: -0.01%
Price: $166.85
Shares after: 5,451,707
Date: 13 Apr 2022
Ownership: Direct
Footnotes: F1, F3

MRNA transaction

Common Stock

Sale

Transaction value: $117,523
Shares: -700
Change %: -0.01%
Price: $167.89
Shares after: 5,451,007
Date: 13 Apr 2022
Ownership: Direct
Footnotes: F1, F4

MRNA transaction

Common Stock

Sale

Transaction value: $191,140
Shares: -1,130
Change %: -0.02%
Price: $169.15
Shares after: 5,449,877
Date: 13 Apr 2022
Ownership: Direct
Footnotes: F1, F5

MRNA transaction

Common Stock

Sale

Transaction value: $223,001
Shares: -1,312
Change %: -0.02%
Price: $169.97
Shares after: 5,448,565
Date: 13 Apr 2022
Ownership: Direct
Footnotes: F1, F6

MRNA transaction

Common Stock

Sale

Transaction value: $530,875
Shares: -3,100
Change %: -0.06%
Price: $171.25
Shares after: 5,445,465
Date: 13 Apr 2022
Ownership: Direct
Footnotes: F1, F7

MRNA transaction

Common Stock

Sale

Transaction value: $331,786
Shares: -1,930
Change %: -0.04%
Price: $171.91
Shares after: 5,443,535
Date: 13 Apr 2022
Ownership: Direct
Footnotes: F1, F8

MRNA transaction

Common Stock

Gift

Transaction value
Shares: -4,000
Change %: -0.07%
Price
Shares after: 5,452,407
Date: 13 Apr 2022
Ownership: Direct
Footnotes: F9, F10

MRNA transaction

Common Stock

Sale

Transaction value: $1,685,900
Shares: -10,000
Change %: -0.14%
Price: $168.59
Shares after: 6,934,880
Date: 14 Apr 2022
Ownership: See Footnote
Footnotes: F11, F12

MRNA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 9,050,372
Date: 13 Apr 2022
Ownership: See Footnote
Footnotes: F13

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 13 footnotes

Footnote F1

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020.

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.22 to $166.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $166.34 to $167.31. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $167.50 to $168.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F5

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $168.53 to $169.52. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F6

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $169.54 to $170.49. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F7

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $170.66 to $171.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F8

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $171.68 to $172.37. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F9

The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020, as amended May 13, 2021.

Footnote F10

The reported disposition represents a bona fide charitable gift made by the reporting person.

Footnote F11

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019.

Footnote F12

These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Footnote F13

These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.